| Literature DB >> 30135801 |
Rony Kayrouz1, Blake F Dear1, Eyal Karin1, Vincent J Fogliati1, Nickolai Titov1.
Abstract
The present pilot study examined the efficacy and acceptability of an internet-delivered Cognitive Behaviour Therapy (iCBT) intervention delivered in both English and Arabic languages to Arab Australians, aged 18 and over, with symptoms of depression and anxiety. Thirteen participants with at least mild symptoms of depression on the (Patient Health Questionnaire 9-item; PHQ-9; total scores ≥ 5) or anxiety (Generalised Anxiety Disorder 7-item; GAD-7; total scores ≥ 5) accessed the online Arabic Wellbeing Course, which consisted of five online lessons delivered over eight weeks with weekly clinician support. Measures of depression, anxiety, distress and disability were administered at pre-treatment, post-treatment and 3-month follow-up. Data were analysed using generalised estimation equation (GEE) modelling. Seventy-seven percent (10/13) of participants completed the five lessons over eight weeks, with 10/13 providing post-treatment and 3-month follow-up data. Participants improved significantly across all outcome measures, with large within-group effect sizes based on estimated marginal means (Cohen's d) at post-treatment (d = 1.18 to 1.62) and 3-month follow-up (d = 1.28 to 1.72). In addition, 40% and 38% of participants obtained, at least, a 50% improvement in symptoms of both anxiety and depression at 3-month follow-up respectively. Participants rated the Arabic Wellbeing Course as acceptable, and 70% of those who completed follow-up questionnaires reported accessing the course in both English and Arabic languages. Notwithstanding the limitations of an open trial design, these results are encouraging and indicate that culturally modified clinician-guided internet-delivered versions of Western psychological interventions have the potential for increasing access to treatment for Arabic-speaking Australians, and potentially other groups.Entities:
Keywords: Anxiety; Arab Australians; Arabic; Depression; Internet-delivered treatment; Transdiagnostic
Year: 2016 PMID: 30135801 PMCID: PMC6096205 DOI: 10.1016/j.invent.2016.06.002
Source DB: PubMed Journal: Internet Interv ISSN: 2214-7829
Fig. 1Participant flow.
Observed and estimated means, standard deviations, confidence intervals and effect sizes (Cohen's d) for the overall sample.
| Observed means | Estimated marginal means | Within group effect sizes (based on estimated means) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | 3-month follow-up | Pre-treatment | Post-treatment | 3-month follow-up | Pre-post | Pre-treatment to 3-month follow-up | Post-treatment to 3-month follow-up | |
| PHQ-9 | 12.53 (4.66) | 6.60 (4.65) | 5.70 (4.42) | 12.54 (4.48) | 6.72 (3.87) | 5.80 (3.68) | 1.39 (0.50–2.20) | 1.64 (0.71–2.47) | 0.24 (− 0.54–1.01) |
| GAD-7 | 11.15 (5.46) | 6.00 (3.37) | 5.00 (5.06) | 11.15 (5.25) | 6.06 (3.14) | 5.05 (4.21) | 1.18 (0.31–1.97) | 1.28 (0.40–2.08) | 0.27 (− 0.51–1.04) |
| SDS | 24.15 (13.37) | 8.90 (9.53) | 7.00 (7.16) | 24.15 (12.84) | 8.92 (7.93) | 6.88 (5.96) | 1.43 (0.53–2.24) | 1.72 (0.78–2.56) | 0.29 (− 0.49–1.05) |
| K10 | 29.62 (8.10) | 18.60 (6.40) | 18.90 (9.45) | 29.62 (7.78) | 18.81 (5.34) | 19.11 (7.87) | 1.62 (0.69–2.45) | 1.34 (0.45–2.15) | − 0.05 (− 0.81–0.0.72) |
Note: Standard deviations and 95% confidence intervals are shown in parentheses. Pre: pre-treatment, post: post-treatment; PHQ-9: Patient Health Questionnaire 9-Item; GAD-7: Generalised Anxiety Disorder 7-Item; SDS: Sheehan Disability Scale; K10: Kessler 10-Item.
Proportion of participants below cut-off scores of clinical significance (remission) and proportion demonstrating at least 50% reduction in pre-treatment scores (recovery) and the average improvement of the group.
| Pre-treatment | Post-treatment | 3-month follow-up | |||||
|---|---|---|---|---|---|---|---|
| ≥ Clinical cut-off | ≤ Clinical cut-off | ≥ 50% improvement | Average improvement | ≤ Clinical cut-off | ≥ 50% improvement | Average improvement | |
| PHQ-9 | 10/13 (76.92%) | 8/13 (61.54%) | 6/13 (46.15%) | 33.10% | 8/13 (61.54%) | 5/13 (38.46%) | 40.38% |
| GAD-7 | 9/13 (69.23%) | 7/13 (53.84%) | 3/13 (23.08%) | 32.06% | 7/13 (53.84%) | 5/13 (38.46%) | 37.77% |
Note: Intention-to-treat model was employed with last-observation being carried forward if follow-up data was not available. The clinical cut-offs utilised for the PHQ-9 and GAD-7 were 10 and 8 respectively.